Anti-Depressant Drugs Market

The global antidepressant drugs market is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030. The demand for antidepressant drugs is primarily being boosted by the increasing number of depression cases around the world, coupled with increasing awareness about depression. Furthermore, the antidepressant drugs market is anticipated to grow on account of a large number of ongoing research activities in this field. Collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the antidepressant drugs market during the forecast period from 2024-2030.

Anti-depressant Drugs Market, segmented by Drug Type (selective Serotonin Reuptake Inhibitors (SSRI), Selective-norepinephrine Reuptake Inhibitors (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitors (MAOI), And Others), Application (Major Depressive Disorder (MDD), Obsessive-compulsive Disorder (OCD), General Anxiety Disorder (GAD), Panic Disorder, And Others), and Geography, is expected to grow at a steady CAGR till 2028 owing to the increasing number of people with depression ( Bipolar Depression, Postpartum Depression, etc.)  and increasing research and development activities.

Anti-Depressant Drugs Market Dynamics:

The continuous rise in cases of psychiatric comorbidities such as depression, obsessive-compulsive disorder, and others is driving the growth of the antidepressant market. As per the data published by the World Health Organization (WHO) in 2022, around 970 million people worldwide, which makes 1 in every 8 people, were living with a mental disorder in 2019. The source further stated that anxiety and depressive disorders, with anxiety affecting 301 million people, including 58 million children and adolescents, were the most common mental disorders globally in 2019.

As per the above-mentioned source, around 280 million people worldwide, making up 3.8% of the global population, including 23 million children and adolescents, were suffering from depression in 2019.

Similarly, ongoing research activities about the novel anti-depressant drugs development will accelerate market growth in the foreseeable future. For example, in November 2022, Autobahn Therapeutics announced the initiation of a Phase I clinical trial of ABX-002 intended for the major depressive disorder treatment.

However, regulatory compliance and other safety concerns associated with antidepressant drugs, along with social stigma, discrimination, and other challenges encountered by people with mental health conditions may restrict the overall antidepressant drugs market size.

Anti-Depressant Drugs Market Segment Analysis:

Anti-Depressant Drugs Market by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRI), Selective-Norepinephrine Reuptake Inhibitors (SNRI), Tricyclic Antidepressants (TCA), Monoamine Oxidase Inhibitors (MAOI), and Others), Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), General Anxiety Disorder (GAD), Panic Disorder (PD), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the Anti-Depressant Drugs market, the Selective-Norepinephrine Reuptake Inhibitor (SNRI) category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the surge in depression cases and anxiety disorders, and the role of Selective-Norepinephrine Reuptake Inhibitors (SNRI) in depression treatment and management.

Serotonin is referred to as the "feel-good hormone" as it facilitates communication between brain cells and supports social behavior, appetite, mood, and overall well-being. It also aids in the regulation of the body's internal clock and sleep-wake cycle.

Another neurotransmitter that is believed to play a role in the control of emotions and mental processes is norepinephrine.

By preventing or postponing the absorption of serotonin and norepinephrine by nerves, selective serotonin-norepinephrine reuptake inhibitors, or SSNRIs, raise serotonin and norepinephrine levels in the brain.

SNRIs assist in easing the depressed symptoms associated with major depressive disorder (MDD), including irritability, poor mood, anxiety, restlessness, and difficulties falling asleep.

For example, Desvenlafaxine, belonging to the serotonin-norepinephrine reuptake inhibitor class, is a medication used to treat depression.

The expanding applications of SNRIs in the treatment of abnormal psychological changes with improved efficacy are going to increase the demand for the same.

Therefore, owing to the above-mentioned factors, the Selective-Norepinephrine Reuptake Inhibitors (SNRI) category is expected to register significant growth, thereby driving the overall antidepressant drugs market growth during the forecast period.

North America Is Expected To Dominate The Overall Anti-Depressant Drugs Market:

Among all the regions, North America is estimated to account for the largest antidepressant drugs market share in the year 2023. Owing to the antidepressant drug market drivers, such as the rising prevalence of neurological disorders, increasing cases of psychiatric disorders, high disposable income, sophisticated healthcare infrastructure, presence of key antidepressant drugs manufacturers, increasing antidepressant drug development activities, and others, the market is expected to witness prosperity in the region during the forecast period 2024-2030.

According to the National Institute of Mental Health (NIMH), in 2022, about 52.9 million people, which stands for 21% of the population, experienced mental illness in 2020 in the United States. As per the same source, 14.2 million people experienced serious mental illness in the US in 2020.

The above-mentioned source further stated that around 21.0 million adults had at least one major depressive episode in 2020 in the United States.

Coupled with the factors mentioned above, the increasing number of antidepressant drug development activities in the region is also going to assist in the antidepressant market growth. For example, in September 2023, the US Food and Drug Administration (FDA) approved a new drug, EXXUA by Fabre-Kramer Pharmaceuticals, to treat major depressive disorder in adults. The drug does not have common side effects found with other antidepressant drugs.

Thus, the above-mentioned factors are likely to propel the growth of the anti-depressant drugs market in the region during the forecast period from 2024-2030.

Key Anti-Depressant Drugs Companies

Some of the key anti-depressant drugs companies operating in the market include - AbbVie Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Organon group of companies, Takeda Pharmaceutical Company Limited, Novartis AG, Biogen Inc., Sage Therapeutics, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, Inc., Lupin, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr Reddy’s Laboratories Ltd., and Others.

Recent Developmental Activities In The Anti-Depressant Drugs Market:

• In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA had approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD).
• In August 2022, the US FDA approved AUVELITY, which is an extended-release dextromethorphan/bupropion tablet intended for the treatment of major depressive disorder in adults.
• In August 2020, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA had approved the supplemental new drug application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Key Takeaways From The Anti-Depressant Drugs Market Report Study

• Anti-Depressant Drugs Market size analysis (2024), and market forecast for 6 years (2024-2030)
• The top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key antidepressant drug companies dominating the global antidepressant market.
• Various anti-depressant drug market opportunities available for the other competitors in the anti-depressant drugs market space.
• What are the top-performing segments in 2024? How will these segments perform in 2030?
• Which are the current top-performing anti-depressant drug market regions and countries?
• Which are the regions and countries where anti-depressant drug companies should have concentrated on opportunities for market growth in the future?

Target Audience Who Can Benefit From The Anti-Depressant Drugs Market Report Study

• Anti-depressant drug manufacturers
• Research organizations and consulting companies
• Anti-Depressant Drugs related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Anti-Depressant Drugs Distributors and Traders
• Various End-users who want to know more about the anti-depressant drugs market and the latest developments in the anti-depressant drugs market.